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ABSTRACT 
Objective: Cognitively engaging lifestyles have been associated with reduced risk of conversion to 
dementia. Multiple mechanisms have been advocated, including increased brain volumes (i.e., 
brain reserve) and reduced disease progression (i.e., brain maintenance). In cross-sectional studies 
of presymptomatic frontotemporal dementia (FTD), higher education has been related to 
increased grey matter volume. Here, we examine the effect of education on grey matter loss over 
time. 
Methods: Two-hundred twenty-nine subjects at-risk of carrying a pathogenic mutation leading to 
FTD underwent longitudinal cognitive assessment and T1-weighted magnetic resonance imaging at 
baseline and at 1-year follow-up. The first principal component score (PC1) of the Graph-Laplacian 
Principal Component Analysis (gLPCA) on 112 grey matter region-of-interest volumes was used to 
summarize the grey matter volume (GMV). The effects of education on cognitive performances 
and GMV at baseline and on the change between 1-year follow-up and baseline (slope) were 
tested by Structural Equation Modeling (SEM). 
Results: Highly educated at-risk subjects had better cognition and higher grey matter volume at 
baseline; moreover, higher educational attainment was associated with slower loss of grey matter 
over time in mutation carriers. 
Conclusions: This longitudinal study demonstrates that even in presence of ongoing pathological 
processes, education may facilitate both brain reserve and brain maintenance in the 
presymptomatic phase of genetic FTD. 
 
Key words: frontotemporal dementia (FTD), brain reserve, brain maintenance, graph theory, 
magnetic resonance imaging (MRI)  
1. INTRODUCTION 
Frontotemporal Dementia (FTD) is a neurodegenerative disorder characterized by executive 
dysfunction, personality changes and language impairment, along with atrophy of frontal and 
temporal lobes.[1, 2] FTD has a strong genetic background with autosomal dominant inheritance 
in around a third of patients. Mutations in Microtubule-Associated Protein Tau (MAPT), Granulin 
(GRN) and chromosome 9 open reading frame 72 (C9orf72) genes are proven major causes of 
genetic FTD, accounting for 10-20% of all FTD cases.[3] 
There is wide variation in the age at onset within genes and within families with the same 
mutation, and possible disease modifiers have been recently reported. Identification of disease 
modifiers is key to correctly select subjects, reduce heterogeneity and increase statistical power of 
analysis of clinical trials, to stage presymptomatic disease and to enable long-term care planning in 
at-risk subjects. 
Genetic variations within Transmembrane Protein 106B (TMEM106B) have been suggested to 
modulate disease onset in Frontotemporal Lobar Degeneration due to TAR DNA binding protein 43 
proteinopathy (FTLD-TDP),[4, 5] and more recently, GDNF Family Receptor Alpha 2 (GFRA2) 
polymorphism and C6orf10/LOC101929163 locus have been further implied in affecting the onset 
in GRN and C9orf72 mutation carriers, respectively.[6, 7] 
Along with non-modifiable genetic determinants, modifiable factors that modulate brain structure 
and function have been identified. For example, educational attainment contributes to resilience 
against brain damage in neurodegenerative disorders including Alzheimer’s disease and FTD,[8, 9] 
in symptomatic and presymptomatic disease stages. In particular, it has been shown that higher 
educational achievements are associated with greater grey matter volumes in presymptomatic 
subjects carrying pathogenic FTD mutations.[10] These findings corroborated previous studies in 
healthy individuals, in which life exposures, such as educational and occupational attainments and 
engagement in leisure and social activities, have been associated with decreased risk of 
developing dementia[11, 12] and with greater brain volumes.[13, 14] 
These results argue that education, a proxy measure of brain reserve, may postpone FTD symptom 
onset; however, these findings cannot give any information on the role of educational attainment 
in counteracting the effect of the pathogenic mutation on brain changes over time, i.e. actively 
coping with pathology progression.[15] This concept, called brain maintenance, cannot be 
measured through cross-sectional data, but requires longitudinal studies.[16] Indeed, if lifetime 
exposures, such as education, influence brain maintenance in at-risk subjects, this would have to 
be carefully evaluated in defining clinical trials’ designs and outcomes and it might itself be 
considered an interventional approach. 
In the present study, we aimed at evaluating the effect of educational attainment on longitudinal 
grey matter changes and cognitive performances in a large cohort of at-risk subjects from the 
Genetic FTD Initiative (GENFI) study.  
2. METHODS 
2.1. Participants 
Data for this study were drawn from the GENFI multicentre cohort study, which consists of 27 
research centres across Europe and Canada (www.genfi.org.uk). For the purpose of the present 
study, we included subjects at-risk of carrying mutations in C9orf72, MAPT and GRN, as having the 
proband with monogenic FTD[17] and for whom both baseline and 1-year follow-up magnetic 
resonance imaging (MRI) was available. Conversion to symptomatic stage at follow-up visit or the 
presence of psychiatric disease or central nervous system pathology, including expansive or 
vascular lesions, were considered exclusion criteria.  
Between January 2012 and December 2017, 229 at-risk subjects fulfilled inclusion/exclusion 
criteria, namely 116 mutation carriers (C9orf72 n=31; GRN n=65; MAPT n=20) and 113 mutation 
non-carriers. 
Local ethics committees approved the study at each site and all participants provided written 
informed consent; the study was conducted according to the Declaration of Helsinki. 
For each subject we recorded demographic data, including years of formal schooling (education), 
past medical history, and a standardized clinical and neuropsychological assessment, as previously 
published.[17] We considered education as reserve proxy and Mini-Mental examination (MMSE) 
raw scores as measure of cognitive status. 
Furthermore, we considered age, sex and TMEM106B genotype (see[10] for details), as variables 
of interest in the statistical model. 
 
MRI processing 
Participants were scanned at their local site on scanners from three different manufacturers 
(Philips Healthcare, GE Healthcare Life Sciences, Siemens Healthcare Diagnostics). Magnetic field 
strength was 3T for 221 scans (96.5%) and 1.5T for 8 scans (3.5%). The protocol, designed to 
match across scanners as much as possible, included a volumetric T1-weighted MRI scan, as 
previously published.[17] 
Baseline and follow-up scans were processed using the standardized longitudinal voxel-based 
morphometry pipeline of the Computational Anatomy Toolbox (CAT v.12.1, extension to SPM12 
v.7219 running on MATLAB R2015a) (http://www.neuro.uni-jena.de/cat/). 
Baseline and follow-up grey matter volume (GMV) maps were parcelled into 112 cortical and 
subcortical regions (excluding the cerebellum because of some subjects with incomplete coverage 
of the inferior cerebellar hemispheres[18]) according to the maximum probability tissue labels 
derived from the “MICCAI 2012 Grand Challenge and Workshop on Multi-Atlas Labeling” 
(https://my.vanderbilt.edu/masi/workshops/). This atlas was created from MRI scans belonging to 
the OASIS project (www.oasis-brains.org/) and labels were provided by Neuromorphometrics, Inc. 
(www.neuromorphometrics.com/). 
Tissue volumes were estimated in the native space, before any spatial normalization. Thus, region 
of interests (ROIs) values, representing the GMV contained in each ROI (expressed in milliliters, 
mL), were further corrected for the total intracranial volume (TIV). Estimates of TIV, total GMV, 
total white matter volume (WMV) and total cerebrospinal fluid volume (CSFV) were also 
computed to assess macroscopic differences. Total GMV, total WMV and total CSFV were 
expressed as percentage of TIV. 
 
2.2. Statistical analysis 
To overcome the complexity of MRI data, graph-Laplacian Principal Component Analysis (gLPCA) 
was applied to obtain a low dimensional representation of grey matter parcellation at baseline 
and at follow-up,[10] which incorporated graph structure. gLPCA has several advantages 
compared to Principal Component Analysis (PCA): (i) it is modelled on the representation of the 
data; (ii) it can be easily calculated, presenting a compact closed-form solution; and (iii) it allows 
noise removal. The first principal component score (PC1) was used to summarise GMV at each 
time point. A correlation threshold higher than 0.6 was used to define PC1, which was constituted 
by 100 ROIs belonging to frontal, cingulate, temporal and parietal regions. 
Successively, a two-group Structural Equation Model (SEM) was fitted on longitudinal data.  
SEM is a multivariate regression technique that models the covariance structure of a set of 
observed and latent (random effects) variables, and is based on a subset of possible paths 
connecting those variables, incorporating directional information (regression coefficients) and bi-
directional information (covariance). 
The study design was reported in Figure 1. We considered mutation carriers and mutation non-
carriers separately. In the two groups, the effect of education was evaluated on a) cognitive 
performances (as measured by MMSE) at baseline; b) GMV (as measured by PC1) at baseline; c) 
the slope of cognitive performances between 1-year follow-up and baseline; d) the slope of GMV 
between 1-year follow-up and baseline. Moreover, we evaluated the effect of e) GMV at baseline 
on the cognitive performances at baseline, f) GMV at baseline on the slope of cognitive 
performances; g) the slope of GMV on the slope of cognitive performances; h) the cognitive 
performances at baseline on the slope of GMV. Finally, we evaluated the covariance between i) 
the baseline and the slope of cognitive performances, and j) the baseline and the slope of GMV. 
Regression effects were adjusted by observed covariates, namely age and sex; in view of previous 
evidence for TMEM106B polymorphism effect on GMV in presymptomatic mutation carriers,[10] 
we also considered TMEM106B genotype (rs1990622 T/T, T/C, C/C, recorded using addictive 
coding 0,1,2), as covariate. 
We did not include random effects (latent covariates), such as family’s pedigree and Country, on 
the basis of an initial exploratory analysis that indicated no significant effects of these variables. 
 
Figure 1 about here. 
 
Baseline and follow-up demographic, cognitive and volumetric variables were compared across 
groups using independent t-test or paired sample t-test for continuous variables and Fisher’s exact 
tests for dichotomous variables. Exploratory Random Effect Models was performed by “lme4” R 
package. SEM analysis was performed via “lavaan” R package, using Full Information Maximum 
Likelihood Method (FIML) for simultaneously estimating SEM parameters and imputing MMSE 
score and TMEM106B genotype random missing values. In addition, for quality control, MMSE 
score and TMEM106B genotype missing values were imputed with Nonparametric Random Forest 
Imputation procedure of the “missForest” R package, and imputed data matrix was successively 
used for SEM analysis. Two-group SEM analysis was performed by an overall Likelihood Ratio Test 
(LRT) of two SEM models: model (1) with unequal regression coefficients, and residual 
(co)variances in the two groups vs. model (0) with equal regression coefficients, and residual 
(co)variances.  Finally, a model (2) was fitted considering the group as covariate and adding the 
interaction terms education*group and TMEM*group, for evaluating the statistical significance of 
the regression coefficient differences between the two-groups.  P-values less than 0.05 were 
considered significant.  
3. RESULTS 
Demographic characteristics of at-risk asymptomatic subjects, i.e. mutation carriers and mutation 
non-carriers, are reported in Table 1. Non-carriers were older than carriers (p=0.036); no other 
significant differences were found in sex, years of schooling, MMSE at baseline and brain volumes 
at baseline between groups. No significant group-wise differences were found in MMSE and brain 
volumes changes at 1-year follow-up in either carriers or non-carriers.  








N° of subjects    
All 116 113 - 
C9orf72, % 26.7 -  
GRN, % 56.0 -  
MAPT, % 17.2 -  
Sex, female % 60.3 58.4 n.s. † 
Education, years 14.4±3.4 14.0±3.2 n.s. 
Age at baseline visit, years 45.7±11.2 49.2±14.0 0.036 
Age at follow-up visit, years 47.1±11.3 50.6±14.1 0.038 
Expected age at onset, years* -12.1±11.5 - - 
MMSE, baseline  29.4±1.2 29.4±0.9 n.s. 
MMSE, follow-up  29.3±1.1 29.4±1.0 n.s. 
TIV baseline, mL 1498±151 1490±123 n.s. 
TIV follow-up, mL 1500±141 1492±128 n.s. 
Total GMV baseline, % 42.8±3.5 42.7±3.7 n.s. 
Total GMV follow-up, % 42.6±3.7 42.6±3.6 n.s. 
Total WMV baseline, % 34.0±2.5 33.6±2.5 n.s. 
Total WMV follow-up, % 33.7±2.5 33.6±2.7 n.s. 
Total CSFV baseline, % 23.1±4.8 23.7±4.8 n.s. 
Total CSFV follow-up, % 23.7±4.9 23.9±4.9 n.s. 
 
^Two sample t-test, otherwise specified: †Fisher’s exact test. 
p refers to mutation carriers vs. mutation non-carriers comparisons; no significant differences 
between baseline vs. follow-up MMSE scores and brain volumes in both mutation non-carriers and 
in mutation carriers were found. Results are expressed as mean  standard deviation, unless 
otherwise specified. 
MMSE: Mini-Mental State Examination; TIV: total intracranial volume; GMV: grey matter volume; 
WMV: white matter volume; CSFV: cerebrospinal fluid volume; n.s.: not significant. 
*computed as previously published [17] 
 
 
SEM fitting results are shown in Table 2 and Figure 2. Overall, the two-group models' difference 
was statistically significant (LRT=34.3, df=20, p-value=0.019). 
In mutation carriers, significant direct effects of education on cognitive performances (as 
measured by MMSE) and on GMV at baseline (as measured by PC1, which summarised ROI 
measures) were found (beta=0.349, 95%CI=0.047 to 0.650, p=0.023 and beta=0.284, 95%CI=0.047 
to 0.521, p=0.019, respectively). Moreover, education had a significant inverse effect on GMV 
slope (beta=0.270, 95%CI=0.501 to 0.041, p=0.021), the higher the years of formal schooling 
the lower the loss of GMV at follow-up. 
No significant effect of education on cognitive performances’ slope at 1-year follow-up was 
observed (beta=0.125, 95%CI=0.174 to 0.423, p=0.413). No direct effect (p>0.05) between 
baseline and slopes of cognitive performances and GMV was observed, while expected significant 
negative covariances were confirmed (cov=0.636, 95%CI=0.869 to 0.402, p<0.001 and 
cov=0.305, 95%CI=0.444 to 0.166, p<0.001 for cognitive performances and GMV, respectively). 
These above effects were similarly present in non-carriers, with the distinctive difference for the 
null effect of education on GMV slope (beta =0.020, 95%CI=0.181 to 0.140, p=0.806). Notably, 
in mutation non-carriers, the significant direct effect of education on cognitive performances was 
greater (two-fold) than in mutation carriers (beta=0.548, 95%CI=0.289 to 0.807, p<0.001). 
Nevertheless, the two-group beta differences (the two-way interaction effect) was statistically 
suggestive in the combined group SEM analysis (p=0.088). 
In addition, a significant covariate effect of TMEM106B genotype was observed in mutation 
carriers, and it was not shown in mutation non-carriers (the two-way interaction testing was 
statistically significant: p=0.041), confirming the previous evidence [10] of the modulating effect of 
TMEM106B genotype on GMV in presymptomatic FTD (beta=0.468, 95%CI=0.189 to 0.747, 
p=0.001 and beta=0.034, 95%CI=0.119 to 0.186, p=0.665 for mutation carriers and non-carriers, 
respectively). 
  
Table 2. Structural Equation Model in mutation carriers and mutation non-carriers. 














MMSE, baseline         
GMV baseline 0.074 0.115 0.644 0.520 -0.025 0.110 -0.231 0.817 
Sex -0.003 0.208 -0.014 0.989 -0.058 0.163 -0.355 0.723 
Age -0.160 0.100 -1.599 0.110 0.006 0.076 0.078 0.938 
TMEM106B 0.147 0.184 0.797 0.425 0.058 0.129 0.447 0.655 
Education 0.349 0.153 2.279 0.023 0.548 0.132 4.145 <0.001 
MMSE, slope         
GMV baseline 0.092 0.122 0.748 0.454 0.101 0.153 0.661 0.509 
GMV slope 0.141 0.109 1298 0.194 0.123 0.185 0.668 0.504 
Sex 0.117 0.208 0.561 0.575 -0.370 0.207 -1.787 0.074 
Age 0.098 0.102 0.961 0.336 -0.200 0.099 -2.013 0.044 
TMEM106B 0.086 0.182 0.470 0.639 -0.249 0.162 -1.533 0.125 
Education 0.125 0.152 0.818 0.413 -0.307 0.166 -1.849 0.065 
GMV, baseline         
Sex 0.104 0.168 0.619 0.536 -0.020 0.140 -0.145 0.884 
Age -0.386 0.072 -5.333 <0.001 -0.428 0.051 -8.424 <0.001 
TMEM106B 0.468 0.142 3.287 0.001 0.086 0.110 0.778 0.437 
Education 0.284 0.121 2.347 0.019 0.277 0.110 2.515 0.012 
GMV, slope         
MMSE baseline -0.043 0.064 -0.664 0.507 -0.017 0.049 -0343 0.731 
Sex -0.357 0.160 -2.235 0.025 -0.178 0.098 -1.814 0.070 
Age -0.060 0.070 -0.857 0.392 -0.009 0.036 -0.256 0.798 
TMEM106B -0.072 0.136 -0.582 0.597 0.034 0.078 0.433 0.665 
Education -0.270 0.117 -2.303 0.021 -0.020 0.082 -0.246 0.806 
 
Covariances         
MMSE baseline with 
MMSE slope 
-0.636 0.119 5.340 <0.001 -0.514 0.096 -5.375 <0.001 
GMV baseline with GMV 
slope 
-0.305 0.071 4.309 <0.001 -0-186 0.038 -4.860 <0.001 
 
MMSE: Mini-mental examination test; GMV: grey matter volume as measured by first component 
(PC1, see text for details); SE: Standard Error; z-value= Estimate/SE. 
Significant results of educational attainment’s effect in boldface. 
 
Figure 2 about here.  
4. DISCUSSION 
Genetic FTD is preceded by a long period in which, despite the evidence of initial changes in 
biomarkers and brain structure, behaviour and cognition are spared.[17, 19-21] 
Pharmacological and non-pharmacological interventions may provide better clinical outcomes if 
applied in this phase, when the brain can still cope with pathology processes, and such treatments 
may eventually delay disease onset.[22] Beyond future disease-modifying drugs,[23] the possibility 
to intervene on environment and other modulating factors is attractive. Some evidence shows 
that cognitive stimulating environments lead to brain volumetric advantages and better cognitive 
performances. These effects are common to physiological[24-26] and initial pathological 
ageing,[27-29] suggesting that neuroplasticity is maintained even in diseased brains, regardless of 
the specific clinical picture or the underlying pathological process. 
Two alternate hypotheses address this issue. First, that lifestyle acts passively by increasing brain 
volume, but does not influence on brain loss; second, lifestyle acts by increasing brain 
maintenance. To test the latter hypothesis longitudinal data is required. These positive effects may 
diminish as disease progresses to the symptomatic phase. If this second hypotheses were the case, 
it would be plausible to think of modulating the disease course of dementing disorders by 
enrichment of lifetime exposures. 
In the current longitudinal study, we applied SEM analysis to test these hypotheses in 
presymptomatic monogenic FTD, evaluating the effect of the educational level on two outcome 
measures of reserve: cognitive performances and grey matter volumes. Our results seem to 
confirm the latter hypothesis, showing that higher education confers higher grey matter volumes 
and greater brain maintenance over time. Additionally, as previously reported,[10,30] TMEM106B 
genotype significantly modulates grey matter volume at baseline in mutation carriers. 
These findings are in line with previous longitudinal studies demonstrating that reserve proxies are 
associated with reduced rate of hippocampal atrophy,[31, 32] reduced rate of brain 
hypometabolism[33] and cerebrospinal fluid biomarkers changes[33] in healthy agers and 
Alzheimer’s disease. 
One intriguing aspect of brain maintenance is that it may reflect differences in the accumulation of 
pathology-related changes.[34, 35] Such demonstration in FTD requires in vivo pathological 
markers (i.e. tau or TDP-43 tracers), which are not currently available.[36] This neuroprotective 
effect may be related to changes at the molecular level, such as increased levels of neurotrophic 
factors[37] and glutamate neurotransmission,[38] or at the cellular level, with increased 
neurogenesis,[39] synaptogenesis[40] and angiogenesis,[41] and might be able to go beyond the 
underlying pathogenic mechanisms related to the specific mutation (GRN, C9ORF72, MAPT) or to 
specific proteinopathy (i.e. TDP-43 or tau). 
Interestingly, as previously reported,[10] years of education had a significant effect on grey matter 
volume even in mutation non-carriers, supporting the idea of a generalizable beneficial effect of 
education. Conversely, in the present work, we did not find any effect of education on brain 
maintenance in mutation non-carriers, but we recognize that this could be likely due to the low 
variance of grey matter volume within 1-year follow-up in healthy subjects. However, longer 
follow-up is necessary to draw definitive conclusions. 
Regarding cognition, higher education led to better cognitive performances at baseline, but not to 
significant effects on cognitive decline. This effect was comparable in mutation carriers and 
mutation non-carriers; of note, in subjects without pathogenic mutations, the beneficial effect of 
education on cognitive performances was greater than in mutation carriers. 
We acknowledge that this study entails some limitations. Despite that education represents an 
environmental factor, it is often immutable because acquired in childhood/young adulthood. Thus, 
the present results do not allow to directly conclude that interventional trials could delay disease 
onset. However, education is known to influence professional attainment, which has been already 
proven a proxy measure of reserve in FTD.[9, 42] Also, we chose MMSE as a global measure of 
cognition, acknowledging that MMSE is affected only close to disease onset[17] and that it does 
not represent the best measure of severity even in symptomatic phases.[43] Thus, the effect of 
more sensitive neuropsychological tests[17] has to be evaluated in future studies, especially to 
assess changes of cognitive performances over time. Moreover, we could not test the effect of 
educational attainment in each mutation due to low sample number: larger samples are needed to 
address this issue. Last, due to the observational nature of the study, data on possible 
confounders, such as concomitant vascular risk factors, were not available. However, in a recent 
large-scale Mendelian randomization study of the related condition, i.e. amyotrophic lateral 
sclerosis, the authors confirmed educational attainment to be an important modulator based on 
genetics.[44] 
In conclusion, these findings extend our knowledge of the reserve theory, demonstrating that in 
presymptomatic FTD the rate of atrophy was influenced by the educational level, with reduced 
grey matter loss in more educated subjects. Thus, even in presence of an ongoing pathological 
process, presymptomatic FTD subjects still maintain a high-performing reserve like in healthy 
brains, virtually turning back the clock of the disease natural history. The demonstration that 
differences in early lifestyle may slow down later disease progression suggests that even in 
monogenic disorders, outcomes are not wholly determined from birth, and this opens exciting 
perspectives for eventually delaying symptom onset. Future confirmatory studies assessing the 
role of other reserve proxies and their effect on longitudinal brain changes in symptomatic 
monogenic and sporadic FTD are needed.  
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FIGURE LEGENDS 
Figure 1. Model design of Structural Equation Model. 
The explanatory variable is enclosed in the blue box, while response variables in green (grey 
matter volume) and pink (Mini-mental examination test) circles. For convenience the indicator 
variables, covariates and error terms are not displayed. An arrow from one variable to another 
indicates that the first variable has a causal influence on the latter. 
Grey arrows indicate the tested effect of education on cognitive performances and grey matter 
volumes; orange arrows indicate the tested effect of grey matter volumes on cognitive 
performances at each time point; purple arrows indicate the tested effects of baseline measures 
on slopes’ measures; blue arrows indicate the tested interaction effects between slopes and 
baseline measures (see Methods for details). 
MMSE: Mini-mental examination test; GMV: grey matter volume; i: intercept; s: slope. 
 
Figure 2. Significant results from the Structural Equation Model. 
Significant effects in either mutation carriers and non-carriers are depicted by dark grey arrows, 
while significant effects only in mutation carriers are depicted by light grey arrows (see Results 
section for details). 
MMSE: Mini-mental examination test; GMV: grey matter volume; i: intercept; s: slope. 
